Clinical Trial Update: ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) [Phase 1]

View source ↗

Summary

The ENABLE-1 Phase 1 trial investigates Toll-like receptor signaling to enhance B-cell lymphoma CAR-T therapy, with the study currently listed as active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Non-hodgkin Lymphoma
• Transformed Follicular Lymphoma

Drugs mentioned

• ENABLE-1 (Toll-like receptor signaling enhancement for B-cell lymphoma CAR-T therapy)

Snippet

Sponsor: Malaghan Institute of Medical Research | Conditions: Lymphomas Non-Hodgkin's B-Cell, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 | Status: ACTIVE_NOT_RECRUITING